Microbion Corp is a clinical-stage pharmaceutical company specializing in the development of innovative compounds to combat resistant and difficult-to-treat infections. Their primary therapeutic candidate, MBN-101, has demonstrated broad-spectrum anti-bacterial efficacy against a wide range of pathogens, including superbugs identified by the CDC. What sets MBN-101 apart is its unique ability to both prevent and eradicate microbial biofilms, making it a promising dual-action treatment for serious and life-threatening infections.

With the potential to become a first-in-class and best-in-class clinical approach, Microbion Corp's groundbreaking research offers hope in the fight against infectious diseases. Committed to excellence, their team of experts collaborates with investors and industry partnerships to drive innovation and deliver high-quality products. Stay informed about their latest developments and breakthroughs by subscribing to their newsletter